Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451484 | 0.80 | PTGS2 (0.60) | PTGS2PTGS1MEN1KMT2AGSK3B | |
| SCHEMBL5448909 | 0.78 | PTGS2 (0.58) | PTGS2PTGS1KMT2AGSK3BALDH1A1 | |
| Gw-406381 SCHEMBL309320 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Gw-406381 SCHEMBL7509921 | 0.76 | PTGS2 (0.98) | PTGS2PTGS1 | |
| SCHEMBL5458900 | 0.76 | PTGS2 (1.00) | PTGS2PTGS1MAPT | |
| SCHEMBL4511717 | 0.73 | PTGS2 (0.81) | PTGS2PTGS1GSK3B | |
| SCHEMBL13226848 | 0.66 | PTGS2 (0.51) | PTGS2PTGS1MEN1KMT2AGSK3B | |
| SCHEMBL4472139 | 0.65 | PTGS1 (0.58) | PTGS2PTGS1MEN1KMT2AGSK3B | |
| SCHEMBL5455747 | 0.64 | PTGS1 (0.57) | PTGS2PTGS1MEN1KMT2AGSK3B | |
| SCHEMBL13325858 | 0.64 | SMN1; SMN2 (0.53) | PTGS2MEN1KMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| EP-1687001-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687000-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1510519-B1 | Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005049034-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050113377-A1 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors | BESWICK PAUL J (GB) | 2005-05-26 | — | — | US | disclosed |
| EP-1510519-A1 | Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-6861429-B2 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6831097-B2 | For therapy of pain, fever, inflammation of a variety of conditions and diseases | SMITHKLINE BEECHAM CORPORATION | 2004-12-14 | — | — | US | disclosed |
| EP-1369421-B1 | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1369421-A1 | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LIMITED (GB) | 2003-12-10 | — | — | EP | disclosed |
| EP-1032575-B1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LTD (GB) | 2003-07-23 | — | — | EP | disclosed |
| US-20030040517-A1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors | SMITHKLINE BEECHAM CORPORATION | 2003-02-27 | — | — | US | disclosed |
| US-20030008872-A1 | 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | BESWICK PAUL JOHN (GB) | 2003-01-09 | — | — | US | disclosed |
| US-6451794-B1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | disclosed |
| EP-1032575-A1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999012930-A1 | 2,3-DIARYL-PYRAZOLO[1,5-B]PYRIDAZINES DERIVATIVES, THEIR PREPA RATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | TPH2, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 13/4885MEN1 4881/4885 |
| US-20050113377-A1 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors | PTGER1, NCOA1, NCOR2 | PTGS2 13/4885PTGS1 4/4885MEN1 3991/4885 |
| US-20030008872-A1 | 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | PTGS1, CBR1, PTGER1 | PTGS2 6/4885PTGS1 1/4885MEN1 3909/4885 |
| US-20030040517-A1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors | CBR1, CRHR1, CRHR2 | PTGS2 17/4885PTGS1 5/4885MEN1 2712/4885 |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | PTGES2, PTGER2, PTGDR2 | PTGS2 5/4885PTGS1 10/4885MEN1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.